tesaglitazar tesaglitazar tesaglitazar (also known as az 242) is a dual peroxisome proliferator-activated receptor agonist with affinity to pparα and pparγ, proposed for the management of type 2 diabetes. tesaglitazarclinical dataatc codenonelegal statuslegal status development terminated identifiers iupac name (2s)-2-ethoxy-3-phenyl]propanoic acid cas number251565-85-2 ypubchem cid208901chemspider180999 nunii6734037o3lkeggd01274 ychemblchembl521632 ncomptox dashboard (epa)dtxsid4048773 echa infocard100.201.079 chemical and physical dataformulac20h24o6smolar mass392.47 g·mol−13d model (jsmol)interactive image smiles cco(cc1=cc=c(c=c1)occc2=cc=c(c=c2)os(=o)(=o)c)c(=o)o inchi inchi=1s/c20h24o6s/c1-3-25-19(20(21)22)14-16-6-8-17(9-7-16)26-13-12-15-4-10-18(11-5-15)27-28(2,23)24/h4-11,19h,3,12-14h2,1-2h3,(h,21,22)/t19-/m0/s1 nkey:cxgtzjyqwsufet-ibgzpjmesa-n n ny (what is this?) (verify) the drug had completed several phase iii clinical trials, however in may, 2006 astrazeneca announced that it had discontinued further development. cardiac toxicity of tesaglitazar is related to mitochondrial toxicity caused by decrease in pparγ coactivator 1-α (ppargc1a, pgc1α) and sirtuin 1 (sirt1).